Ironwood Pharmaceuticals shares surge 10.39% intraday as it advances apraglutide for SBS treatment following 2023 acquisition of VectivBio.

Ironwood Pharmaceuticals surged 10.39% intraday, driven by its Q3 report highlighting progress on apreglutide for short bowel syndrome (SBS) treatment and cash reserves sufficient for over 12 months of operations, alongside the 2023 acquisition of VectivBio to advance apreglutide as a next-generation GLP-2 analog in the SBS market. The company focuses on developing innovative therapies for gastrointestinal and metabolic disorders.